Predictive Value of Decreasing Antithrombin III in Deep-Vein Thrombosis

Thorkild Lund Andreasen

doi:10.1055/s-0038-1650103

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1980; 44(03): 135-137
DOI: 10.1055/s-0038-1650103

Original Article

Schattauer GmbH Stuttgart

Predictive Value of Decreasing Antithrombin III in Deep-Vein Thrombosis

Thorkild Lund Andreasen

The Dept. of Clinical Chemistry CL, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark

› Author Affiliations

Abstract

PDF Download

Summary

Antithrombin III (At-III) was measured at the time of admission and two days later in 131 patients laid up in a coronary care unit. The patients were examined for deep-vein thrombosis (DVT) clinically and by means of ¹²⁵I-fibrinogen scanning. 19 patients developed DVT. In 11 subjects with and 25 without DVT At-III decreased more than 10%. And in 7 with and 17 without DVT At-III decreased more than 15%. One person with DVT had subnormal At-III. By using decrease of At-III or subnormal initial At-III to predict DVT the following predictive value (PV) were found. Decrease ≤ 10%, PV pos.= 0.32 and PV neg. = 0.93. Decrease ≤ 15%, PV pos. = 0.32 and PV neg. = 0.90. The positive predictive values obtained were too low to let decreasing At-III give occasion for prophylactic anticoagulant treatment.

Key words

Antithrombin III - Decrease - Deep-vein thrombosis - Predictive values - Myocardial infarction

PDF (705 kb)

References

References
1 Andreasen TL. Automated two-stage assay for determination of antithrombin III with a centrifugal analyzer. Haemostasis 1980; 9: 65-70
2 Bick RL, Dukes ML, Wilson WL, Fekete LF. Antithrombin III as a diagnostic aid in dissiminated intravascular coagulation. Thromb Res 1977; 10: 721-729
3 Chandra S, Hang NU, Marks C. Radiolabelled at III as a probe for the detection of activation of blood coagulation in vivo. Thromb Res 1976; 9: 9-23
4 Collen D, Schertz F, Cock F, De Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man. Effects of venous thrombosis and of heparin administration. Eur J clin Invest 1977; 7: 27-35
5 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath haemorrh 1965; 13: 516-530
6 Laurell CB. Electroimmunoassay. Scand J clin Lab Invest 1972; 29 suppl. 124, pp. 21-37
7 Rosenberg RD. Actions and interactions of antithrombin and heparin. New Engl J Med 1975; 292: 146-151
8 Sagar S, Stamatakis JD, Thomas DP, Kakkar VV. Oral contraceptives, antithrombin III activity, and postoperative deep-vein thrombosis. Lancet 1976; i: 509-511
9 Sas G, Blasko D, Banhegyl D, Jako J, Palos LA. Abnormal antithrombin III (antithrombin III Budapest) as a cause of familial thrombophilia. Thromb Diath haemorrh 1974; 32: 105-115
10 Seegers WH. Antithrombin III. Theory and clinical applications. Am J clin Pathol 1978; 69: 367-375
11 Sixma JJ. Techniques for diagnosing prethrombotic states. A review. Thromb Haemostas 1978; (Stuttg.) 40: 252-259
12 Stormorken H. Studies on antithrombin III using chromozym TH; in: New methods for the analysis of coagulation using chromogenic substrates. Proc Symp Dt Ges klin Chem Titisee 1976 pp: 119-121 (de Gruyter, Berlin 1977)
13 Thaler E, Balzar E, Kopsa H, Pinggera WF. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis 1978; 7: 257-272
14 Ødegård OR, Lie M, Abildgård U. Heparin cofactor activity measured with an amidolytic method. Thromb Res 1975; 6: 287-294
15 Ødegård OR, Rosenlund B, Ervik E. Automated antithrombin III assay with a centrifugal analyzer. Haemostasis 1978; 7: 202-209
16 Ødegård OR, Teien AN. Antithrombin III, heparin co-factor and antifactor X₃ in a clinical material. Thromb Res 1976; 8: 173-178
17 Vinazzer H. Photometric assay of antithrombin III with a chromogenic substrate. Haemostasis 1975; 4: 101-109